IPO
Key Metrics
Company Snapshot
Apnimed is a Biotech company, based in Cambridge, Massachusetts, USA, founded 2017. Market cap $1.52B (As of Sep 4, 2026, stockanalysis.com).
Recent changes
- Sep 4, 2026Sep 4, 2026First reported market cap: $1.52B stockanalysis.com
- Jul 31, 2026Jul 31, 2026Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill Pulse story
- Jul 31, 2026Jul 31, 2026Apnimed Prices Upsized IPO at $16, Raises $192M Pulse story
- Jul 27, 2026Jul 27, 2026IPO $150M Bloomberg
- Jul 27, 2026Jul 27, 2026Apnimed Launches $150M IPO for Sleep Apnea Pill Pulse story
Earlier changes (2)
- Jul 27, 2026Jul 27, 2026Apnimed Launches $150M IPO For First Sleep Apnea Pill Pulse story
- Jul 10, 2026Jul 10, 2026Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jul 27, 2026 | ipo | $150M | — | Pulse story |
Investors
Latest Pulse
- Aug 3, 2026Consumer IPOs Are Getting Crushed While Biotech PopsJersey Mike's opened 9% below its IPO price the same day Reformation traded flat, while Apnimed popped 37.5% days later -- public investors are rewarding unmet-need biotech and discounting mature consumer brands.→
- Jul 31, 2026Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea PillApnimed shares jumped as much as 37.5% in their Nasdaq debut after the Phase 3 biotech priced its upsized IPO at $16 a share, raising $192 million to fund what could become the first FDA-approved pill for obstructive sleep apnea.→
- Jul 31, 2026Apnimed Prices Upsized IPO at $16, Raises $192MApnimed priced an upsized IPO at $16 per share, raising $192 million ahead of its Nasdaq debut under ticker APMD, betting on the first potential FDA-approved pill for obstructive sleep apnea.→
- Jul 27, 2026Apnimed Launches $150M IPO for Sleep Apnea PillApnimed launched a $150-160 million IPO for a pill that could become the first FDA-approved treatment for obstructive sleep apnea.→
- Jul 27, 2026Apnimed Launches $150M IPO For First Sleep Apnea PillShionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.→
- Jul 10, 2026Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea PillApnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.→
Coverage Timeline
newest first- Aug 3, 2026IPOConsumer IPOs Are Getting Crushed While Biotech Pops→
- Jul 31, 2026IPOApnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill$192M IPO→
- Jul 31, 2026IPOApnimed Prices Upsized IPO at $16, Raises $192M$192M IPO→
- Jul 27, 2026IPOApnimed Launches $150M IPO for Sleep Apnea Pill$150M-$160M IPO→
- Jul 27, 2026IPOApnimed Launches $150M IPO For First Sleep Apnea Pillup to $150M IPO→
- Jul 10, 2026IPOApnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill→
All Coverage
IPO
Consumer IPOs Are Getting Crushed While Biotech Pops
Jersey Mike's opened 9% below its IPO price the same day Reformation traded flat, while Apnimed popped 37.5% days later -- public investors are rewarding unmet-need biotech and discounting mature consumer brands.
IPO
Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill
IPO$192M IPO
Apnimed Soars 37% in Nasdaq Debut for Sleep Apnea Pill
Apnimed shares jumped as much as 37.5% in their Nasdaq debut after the Phase 3 biotech priced its upsized IPO at $16 a share, raising $192 million to fund what could become the first FDA-approved pill for obstructive sleep apnea.
IPO
Apnimed Prices Upsized IPO at $16, Raises $192M
IPO$192M IPO
Apnimed Prices Upsized IPO at $16, Raises $192M
Apnimed priced an upsized IPO at $16 per share, raising $192 million ahead of its Nasdaq debut under ticker APMD, betting on the first potential FDA-approved pill for obstructive sleep apnea.
IPO
Apnimed Launches $150M IPO for Sleep Apnea Pill
IPO$150M-$160M IPO
Apnimed Launches $150M IPO for Sleep Apnea Pill
Apnimed launched a $150-160 million IPO for a pill that could become the first FDA-approved treatment for obstructive sleep apnea.
IPO
Apnimed Launches $150M IPO For First Sleep Apnea Pill
IPOup to $150M IPO
Apnimed Launches $150M IPO For First Sleep Apnea Pill
Shionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.
IPO
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
IPO
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
Apnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.
Related Companies
Sources & methodologyshow
Where these figures come from
- Bloombergmajor outlet1 fact
- stockanalysis.comresearch database1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.